ID   TOM-1
AC   CVCL_1895
SY   TOM1
DR   BioSample; SAMN03473484
DR   Cosmic; 1012125
DR   Cosmic; 1026577
DR   Cosmic; 1524825
DR   Cosmic; 2491093
DR   Cosmic; 2649234
DR   DSMZ; ACC-578
DR   DSMZCellDive; ACC-578
DR   GEO; GSM236808
DR   GEO; GSM236844
DR   Wikidata; Q54972778
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1884023;
RX   PubMed=3103721;
RX   PubMed=3332852;
RX   PubMed=9067587;
RX   PubMed=10071072;
RX   PubMed=10576511;
RX   PubMed=16408098;
CC   Population: Japanese.
CC   Doubling time: ~60-70 hours (DSMZ=ACC-578).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 1 fused to ABL1 exon 2 (e1a2 transcript) (PubMed=10071072; PubMed=10576511; PubMed=3103721).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): DSMZ=ACC-578
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,11
ST   D16S539: 9,10
ST   D18S51: 13,15
ST   D19S433: 14,15
ST   D21S11: 31,33.2
ST   D2S1338: 18
ST   D3S1358: 16,17
ST   D5S818: 11,13
ST   D7S820: 10,12
ST   D8S1179: 13,14
ST   FGA: 19,23
ST   Penta D: 10,12
ST   Penta E: 11,18
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C114819; Adult B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2) BCR-ABL1
DI   ORDO; Orphanet_585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 25
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=1884023; DOI=10.1182/blood.V78.6.1574.1574;
RA   Okabe M., Kunieda Y., Sugiwura T., Tanaka M., Miyagishima T., Saiki I.,
RA   Minagawa T., Kurosawa M., Itaya T., Miyazaki T.;
RT   "Inhibitory effect of interleukin-4 on the in vitro growth of
RT   Ph1-positive acute lymphoblastic leukemia cells.";
RL   Blood 78:1574-1580(1991).
//
RX   PubMed=3103721; DOI=10.1182/blood.V69.4.990.990;
RA   Okabe M., Matsushima S., Morioka M., Kobayashi M., Abe S.,
RA   Sakurada K., Kakinuma M., Miyazaki T.;
RT   "Establishment and characterization of a cell line, TOM-1, derived
RT   from a patient with Philadelphia chromosome-positive acute lymphocytic
RT   leukemia.";
RL   Blood 69:990-998(1987).
//
RX   PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9;
RA   Keating A.;
RT   "Ph positive CML cell lines.";
RL   Baillieres Clin. Haematol. 1:1021-1029(1987).
//
RX   PubMed=9067587; DOI=10.1038/sj.leu.2400571;
RA   Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A.,
RA   Janssen J.W.G., Drexler H.G.;
RT   "Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in
RT   human early B-lineage leukemia cell lines.";
RL   Leukemia 11:441-447(1997).
//
RX   PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//
RX   PubMed=10576511; DOI=10.1016/S0145-2126(99)00131-9;
RA   Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.;
RT   "ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.";
RL   Leuk. Res. 23:1055-1060(1999).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//